Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep;186(6):887-899.
doi: 10.1111/bjh.15998. Epub 2019 Jun 5.

Identification of genetic biomarkers for alloimmunization in sickle cell disease

Sanne M Meinderts  1 , Jorn J Gerritsma  2   3 , Joep W R Sins  2   3 , Martin de Boer  1 , Karin van Leeuwen  1 , Bart J Biemond  4 , Anita W Rijneveld  5 , Jean-Louis H Kerkhoffs  6 , Anoosha Habibi  7 , Robin van Bruggen  1 , Taco W Kuijpers  1   2 , Ellen van der Schoot  8 , France Pirenne  9 , Karin Fijnvandraat  2   3 , Michael W Tanck  10 , Timo K van den Berg  1   11
Affiliations
Clinical Trial

Identification of genetic biomarkers for alloimmunization in sickle cell disease

Sanne M Meinderts et al. Br J Haematol. 2019 Sep.

Abstract

Most sickle cell disease (SCD) patients rely on blood transfusion as their main treatment strategy. However, frequent blood transfusion poses the risk of alloimmunization. On average, 30% of SCD patients will alloimmunize while other patient groups form antibodies less frequently. Identification of genetic markers may help to predict which patients are at risk to form alloantibodies. The aim of this study was to evaluate whether genetic variations in the Toll-like receptor pathway or in genes previously associated with antibody-mediated conditions are associated with red blood cell (RBC) alloimmunization in a cohort of SCD patients. In this case-control study, cases had a documented history of alloimmunization while controls had received ≥20 RBC units without alloantibody formation. We used a customized single nucleotide polymorphism (SNP) panel to genotype 690 SNPs in 275 (130 controls, 145 cases) patients. Frequencies were compared using multiple logistic regression analysis. In our primary analysis, no SNPs were found to be significantly associated with alloimmunization after correction for multiple testing. However, in a secondary analysis with a less stringent threshold for significance we found 19 moderately associated SNPs. Among others, SNPs in TLR1/TANK and MALT1 were associated with a higher alloimmunization risk, while SNPs in STAM/IFNAR1 and STAT4 conferred a lower alloimmunization risk.

Keywords: TOLL-like receptors; alloimmunization; gene polymorphisms; responder; sickle cell disease.

PubMed Disclaimer

Comment in

References

    1. Akira, S., Uematsu, S. & Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell, 124, 783-801.
    1. Alarif, L., Castro, O., Ofosu, M., Dunston, G. & Scott, R.B. (1986) HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clinical Immunology and Immunopathology, 38, 178-83.
    1. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413, 732-738.
    1. de Almeida, E.R. & Petzl-Erler, M.L. (2013) Expression of genes involved in susceptibility to multifactorial autoimmune diseases: estimating genotype effects. International Journal of Immunogenetics, 40, 178-185.
    1. Barnes, K.C. (2006) Genetic epidemiology of health disparities in allergy and clinical immunology. The Journal of Allergy and Clinical Immunology, 117, 243-254, quiz 255-6.

LinkOut - more resources